Adalimumab biosimilar(Beijing Science Sun/Beijing Lvzhu)

阿达木单抗生物类似药（北京赛升/北京绿竹）

Report date: 2022/03/15 16:55:26

Base Information

Drug NameAdalimumab biosimilar(Beijing Science Sun/Beijing Lvzhu)
Drug Alias Name阿达利单抗阿达利木单抗阿达莫单抗阿达姆单抗K-3 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisColitis, UlcerativeArthritis, Rheumatoid +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBeijing Science Sun Pharmaceutical Co LtdBeijing Lvzhu Biological Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Science Sun Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisColitis, UlcerativeArthritis, Rheumatoid +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG